A pilot study of atorvastatin treatment in dyslipemid,
non-alcoholic fatty liver patients
E. GO´MEZ-DOMI´NGUEZ, J . P . GISBERT, J . A . MORENO-MONTEAGUDO, L . GARCI´A-BUEY
& R. MORENO-OTERO
Gastroenterology and Hepatology
Service, Hospital Universitario la
Princesa and Instituto de Salud
Carlos III, Madrid, Spain
Correspondence to:
Dr R. Moreno-Otero, Gastroenterology
Service, Hospital Universitario de la
Princesa, Diego de Leo´n 62, E-2806
Madrid, Spain.
E-mail:
rmoreno.hlpr@salud.madrid.org
Publication data
Submitted 28 January 2006
First decision 27 February 2006
Resubmitted 7 March 2006
Accepted 11 March 2006
SUMMARY
Background
Non-alcoholic fatty liver disease (NAFLD) encompasses a wide spectrum
of liver injury. Currently, there are no proven effective therapies avail-
able. Atorvastatin is a new 3-hydroxy-3-metylglutaryl coenzyme A
reductase inhibitor that reduces lipid serum levels.
Aim
To evaluate the effectiveness and safety of atorvastatin in dyslipemid,
non-alcoholic fatty liver patients.
Patients and methods
We prospectively enrolled 25 patients with NAFLD; 22 of them comple-
ted the study. Body mass index, serum lipids, liver function tests and
liver density assessed by echography were measured at baseline and
after 1, 3, 6, 9 and 12 months of treatment. Normalization of transam-
inases and/or improvement in liver density were treatment end points.
Patients received atorvastatin (10–80 mg/daily) according to basal
serum choleresterol levels; additionally, they were given standard
weight-loss counselling and encouraged to follow a low fat diet.
Results
All 22 patients (14 men, mean age 47 � 10 years) had high cholesterol
levels at baseline and 11 (44%) also presented high trygliceride levels.
After 6 months of treatment, eight patients (36.3%) presented normal
transaminase levels. The remaining patients continued treatment for
12 months when 20% of patients presented with normal transaminase
levels, while the other patients showed a 10% reduction in basal levels.
Mean cholesterol levels were 268.5 � 44.2 and 186.8 � 14.4 mg/dL
before and after treatment, respectively (P < 0.05). The mean body mass
index was 27.4 � 3.1 at baseline and 26.3 � 2.8 kg/cm2 at the end of
treatment (P > 0.05). No side effects were reported.
Conclusions
Serum aminotransferase and lipid levels were reduced significantly in all
patients with atorvastatin treatment. Therapy with atorvastatin in NAFLD
patients with hyperlipidemia was found to be both effective and safe.
Aliment Pharmacol Ther 23, 1643–1647
Alimentary Pharmacology & Therapeutics
ª 2006 The Authors 1643
Journal compilation ª 2006 Blackwell Publishing Ltd
doi:10.1111/j.1365-2036.2006.02926.x
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) encom-
passes a range of progressive conditions.1–3 Its natural
history is not yet well understood, but it is currently
believed that patients with steatosis alone rarely
deteriorate over time, 4–6 and has been demonstrated
with the increasing incidence of obesity and diabetes
in Western countries, NAFLD has become a growing
problem. Although its true prevalence is unknown,
some estimates suggest that it might affect one-third
of American adults – a figure also suggested for
Europe and Japan.7–11
Non-alcoholic fatty liver disease, is the hepatic
manifestation of the metabolic syndrome that encom-
passes central obesity, hypertension, hypertriglyce-
ridaemia, low levels of high-density lipoprotein
cholesterol and hyperglycaemia.8–10, 12 The pathogene-
sis of NAFLD includes two steps: first, the healthy liver
becomes steatotic; then, the second step is elicited by
oxidative stress and cytokine synthesis. This leads to
exacerbation of insulin resistance, followed by oxida-
tive stress and organelle dysfunction within liver cells,
resulting in an inflammatory process, hepatocellular
degeneration and fibrosis.13
Currently, there are no proven effective therapies
available for the treatment of NAFLD and strategies
have mainly led to treat or control underlying risk
factors.1–4, 7, 11, 14 Promising pharmacological treat-
ments have been observed with the use of anti-
oxidants, insulin sensitizers, hepatoprotectants or
lipid-lowering agents. Therapeutic results have been
demonstrated with multiple agents and currently
larger randomized trials are underway; these will
hopefully clarify the role of specific pharmacological
treatments.8, 11, 14 Control of hyperlipaemia with
hypolipaemic drugs is controversial in these patients.
Approximately 80% have elevated choleresterol and
triglyceride serum levels. Controlling elevated levels
of cholesterol and triglycerides with diet, exercise
and cholesterol-lowering medications may help to
stabilize or reverse NAFLD.8, 15–18 Atorvastatin, an
inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A
(HMG-CoA) reductase, catalyses the conversion of
HMG-CoA to mevalonate, an early and rate-limiting
step in cholesterol biosynthesis.19–23 The aim of our
pilot study was to evaluate the effectiveness and
safety of atorvastatin in the treatment of patients
with NAFLD.
PATIENTS AND METHODS
We prospectively enrolled patients after satisfying the
following inclusion criteria: (i) abnormal results on
liver test during the 6 months prior to enrolment;
(ii) fatty liver disease assesses by ecography; (iii) no
clinical or serological evidence of other chronic liver
disease; and (iv) no history of alcohol abuse or other
identifiable causes of fatty liver disease. Body mass
index (BMI), serum lipids, liver function test and liver
density assessed by echography were measured at
baseline and after 1, 3, 6, 9 and 12 months of treat-
ment. Because of the fact that all our patients were
asymptomatic and without clinical or ecographic
signs of advanced liver disease, no biopsies were
performed.
All patients received atorvastatin (10–80 mg/daily)
according to basal choleresterol level for 6 or
12 months until obtaining the end point of treatment.
Normalization of transaminases and/or improvement
in liver density were considered as the end point of
treatment. Additionally, all patients were given stand-
ard weight-loss counselling and encouraged to follow
a low fat diet. Although rare, hepatotoxicity has been
reported with atorvastatin. Therefore, subjects made
monitoring visits to our centre to ensure safety and
adherence. Before participating in the study each sub-
ject gave written voluntary assent and consent. All
study variables were treated as continuous variables.
Summary outcome measures were reported as
mean � s.d. For all analyses, a two-tailed P < 0.05
was considered significant. Statistical software used
was SPSS 11.05 for windows (Chicago , IL, USA).
RESULTS
Twenty-five subjects were enrolled, 22 patients, 14
men, with a mean age of 47 � 10 years completed the
study. At baseline, all patients had high cholesterol
levels and 11 of them (44%) also presented high
triglyceride levels. There were five diabetic patients
and in two patients hyperglycaemia was diagnosed
during treatment. Baseline data are shown in Table 1.
After 6 months of treatment, eight patients (36.3%)
presented normal transaminase levels. The remaining
patients continued treatment for 12 months, and at
that moment, 20% of patients presented normal
transaminase levels, while the other patients showed a
10% reduction in basal levels (Figures 1–3). Mean
1644 E . GO´MEZ-DOMI´NGUEZ et al.
ª 2006 The Authors, Aliment Pharmacol Ther 23, 1643–1647
Journal compilation ª 2006 Blackwell Publishing Ltd
choleresterol levels were 268.5 � 44.2 and 186.8 �
14.4 mg/dL before and after treatment, respectively,
with a significant difference between them (P < 0.05).
The mean BMI was 27.4 � 3.1 at baseline and
26.3 � 2.8 kg/cm2 at the end of treatment (P > 0.05).
Liver fat measured by echography and analysed by the
same gastroenterologist did not change significantly
after treatment. There was no statistical difference
between clinical and epidemiological variables in both
groups, 6 and 12 months of treatment. No side effects
were reported in our study.
DISCUSSION
Non-alcoholic fatty liver disease, a spectrum of liver
disorders characterized by the accumulation of fat in
hepatocytes, is the hepatic manifestation of meta-
bolic syndrome.1, 4, 7, 12 The relevance of this condi-
tion is illustrated by two ominous facts: (i) it may
progress to severe liver disease including cirrhosis,
hepatocellular carcinoma or even rapidly progressive
liver failure,9–11 and (ii) it could become the most
common form of liver disease in the near future.4–
7, 12 All subjects enrolled in our study had typical
epidemiological features: middle age with metabolic
risk factors.11, 15 All were asymptomatic and NAFLD
was detected because of abnormal results of liver
tests performed for unrelated issues. Diagnosis inclu-
ded fatty liver disease assessed by ecography and
several exclusion criteria: no clinical or serological
evidence of other chronic liver disease and no his-
tory of alcohol abuse or other identifiable causes of
fatty liver disease.24, 25
Regarding clinical management, changes in life hab-
its had demonstrated efficacy in a previous series.11 A
diet low in calories and saturated fat and an exercise
programme, even when patients are not overweight or
obese, may reduce inflammation, lower elevated levels
of liver enzymes and decrease insulin resist-
ance.7, 16, 17, 24 However, in clinical practice, the
impact of these counsellings are often very modest
and allow patients not to follow any therapeutic
strategies.11, 14 Two of our patients did not know that
they were diabetic at the moment of inclusion and
they presented complications of this disease. Neverthe-
less, all our patients had known for at least 12 months
before being enrolled in the study that they had
dyslipaemia and were overweight, but they had
not changed their way of lifestyle.
In the current study, no statistical changes in weight
loss were observed. However, aminotransfereses, cho-
lesterol and triglyceride serum levels significantly
improved. The absence of a control group limited
the ability to determine the true impact of pharmaco-
therapy, but considering that these parameters did not
previously improve treatment it is possible that the
beneficial effects seen in this study were caused by
atorvastatin. After 6 months of treatment, eight
patients (36.3%) presented normal transaminase levels.
The remaining continued treatment for 12 months and
at that moment, 20% of them presented normal transa-
minase levels. There was significant improvement in
Table 1. Clinical and laboratory features before treatment
Age (years) 47 � 10
Gender (% male) 56
Hypercholesterolaemia (%) 100
Hypertriglyceridae (%) 44
Hyperglycaemia (%) 28
Basal aminotransferases (U/I)
AST 46.7 � 20.5
ALT 72.7 � 44.1
GGT 137.5 � 80.1
ALP 101.1 � 37.6
Weight (kg) 77.8 � 12.5
BMI (kg/cm2) 27.4 � 3.1
Cholesterol (mg/dL) 268.3 � 44.2
Triglyceride (mg/dL) 236.2 � 193.4
Data shown as mean � s.d. AST, aspartate amino trans-
ferase; ALT, alanine amino transferase; GGT, gammaglutamil
transpeptidase; ALP, alkaline phosphatase; BMI, Body mass
index.
0
50
100
150
200
250
300
Week 0 Week 12 Week 24 Week 36 Week 48
GGT
AST
ALT
Figure 1. Mean aminotransferase and gammaglutamil
transpeptidase serum levels at baseline and during treat-
ment with atorvastatin.
ATORVASTATIN TREATMENT IN NON-ALCOHOLIC FATTY L IVER PATIENTS 1645
ª 2006 The Authors, Aliment Pharmacol Ther 23, 1643–1647
Journal compilation ª 2006 Blackwell Publishing Ltd
aminotransferase levels at baseline and at the end of
treatment in both groups (Figures 1–3).
Currently, there are no proven effective therapies
available for the treatment of NAFLD and strategies
have mainly led to treat or control underlying risk fac-
tors.7, 11, 14–18, 21 Atorvastatin is an inhibitor of HMG-
CoA reductase. This enzyme catalyses the conversion
of HMG-CoA to mevalonate, and early and rate-limi-
ting step in cholesterol biosynthesis.18–22 Previous data
about treatment with atorvastatin in NAFLD patients
are promising11, 14 and although statin drugs can have
adverse effects on muscles and the liver, these effects
are uncommon.26–29 In our series, all patients who
received treatment with atorvastatin showed a reduc-
tion in their cholesterol, triglycerides and serum ami-
notransferase levels. Moreover, we found no significant
elevation of liver enzymes during atorvastatin treat-
ment and no adverse effects were observed.
In conclusion, serum aminotransferase and lipid
levels were reduced significantly in all patients with
atorvastatin treatment, although there were no rele-
(a)
(b)
(c)
0
10
20
30
40
50
60
70
80
90
AST baseline AST end of treatment
0
20
40
60
80
100
120
ALT baseline ALT end of treatment
0
50
100
150
200
250
300
350
GGT baseline GGT end of treatment
Figure 3. Patients after 48 weeks of treatment. Paired
values for subjects before and after treatment of (a) aspar-
tate amino transferase, (b) alanine amino transferase and
(c) gammaglutamil transpeptidase.
20
0
40
60
80
100
120
AST baseline AST end of treatment
0
50
100
150
200
250
300
ALT baseline ALT end of treatment
0
20
40
60
80
100
120
140
160
GGT baseline GGT end of treatment
(a)
(b)
(c)
Figure 2. Patients after 24 weeks of treatment. Paired
values for subjects before and after treatment of (a) aspar-
tate amino transferase, (b) alanine amino transferase and
(c) gammaglutamil transpeptidase.
1646 E . GO´MEZ-DOMI´NGUEZ et al.
ª 2006 The Authors, Aliment Pharmacol Ther 23, 1643–1647
Journal compilation ª 2006 Blackwell Publishing Ltd
vant changes in patient’s habits as demonstrated by no
reduction in BMI. The use of atorvastatin in NAFLD
patients with hyperlipidaemia was found to be both
effective and safe. Consequently, multicentre, con-
trolled clinical trials using this drug are warranted.
ACKNOWLEDGEMENT
Supported in part (grant 03/02) by the Instituto de
Salud Carlos III, Madrid.
REFERENCES
1 Ludwig J, Viggiano TR, McGill DB, Ott
BJ. Non-alcoholic steatohepatitis. Mayo
Clinic experiences with a hitherto
unnamed disease. Mayo Clin Proc 1980;
55: 434–8.
2 Ludwig J, McGill DB, Lindor KD. Review:
non-alcoholic steatohepatitis. J Gast-
roenterol Hepatol 1997; 12: 398–403.
3 Sheth SG, Gordon FD, Chopra S. Non-
alcoholic steatohepatitis. Ann Intern
Med 1997; 126: 137–45.
4 Hui AY, Wong VWS, Chan HLY, et al.
Histological progression of non-alco-
holic fatty liver disease in Chinese
patients. Aliment Pharmacol Ther 2005;
21: 407–413.
5 Wong VW, Chan HL, Hui AY, et al.
Clinical and histological features of
non-alcoholic fatty liver disease in
Hong-Kong Chinese. Aliment Pharmacol
Ther 2004; 20: 45–9.
6 Fassio E, Alvarez E, Domı´nguez N, et al.
Natural history of non-alcoholic steato-
hepatitis: a longitudinal study of repeat
liver biopsies. Hepatology 2004; 40:
820–6.
7 American Gastroenterological Associ-
ation medical position statement: non-
alcoholic fatty liver disease. American
Gastroenterological Association. Gastro-
enterology 2002; 123: 1702–4.
8 Ramesh S, Sanval AJH. Evaluation and
management of non-alcoholic steato-
hepatitis. J Hepatol 2005; 42 (Suppl. 1):
S2–12.
9 Bacon BR, Farahvash MJ, Janney CG,
Neuschwander-Tetri BA. Non-alcoholic
steatohepatitis: an expanded clinical
entity. Gastroenterology 1994; 107:
1103–9.
10 Caldwell S, Oelsner D, Iezzoni J, Hes-
penheide E, Battle E, Driscoll C. Crypto-
genic cirrhosis. Clinical characterization
and risk factors for underlying disease.
Hepatology 1999; 29: 664–9.
11 Comar KM, Sterling RK. Review article:
drug therapy for non-alcoholic fatty
liver disease. Aliment Pharmacol Ther
2005; 23: 207–15.
12 Matteoni CA, Younossi ZM, Gramlich T,
Boparai N, Liu YC, McCullough AJ. Non-
alcoholic fatty liver disease: a spectrum
of clinical and pathological severity.
Gastroenterology 1999; 116: 1413–9.
13 Medina J, Ferna´ndez-Salazar LI, Garcı´a-
Buey L, et al. Approach to the patho-
genesis and treatment of non-alcoholic
steatohepatitis. Diabetes Care 2004; 27:
2057–66.
14 Marchesini G, Natale R, Manini R, et al.
Review article: the treatment of fatty
liver disease associated with the meta-
bolic syndrome. Aliment Pharmacol
Ther 2005; 22 (Suppl. 2): 17–9.
15 Oonawala A, Nair S, Thuluvath P. Pre-
valence of obesity and diabetes in
patients with cryptogenic cirrhosis. Hep-
atology 2000; 32: 689–91.
16 Ueno T, Sugawara H, Sujaku K, et al.
Therapeutic effects of restricted diet and
exercise in obese patients with fatty
liver. J Hepatol 1997; 27: 103–7.
17 Andersen T, Gluud C, Franzmann MB,
Christoffersen P. Hepatic effects of diet-
ary weight loss in morbidity obese sub-
jects. J Hepatol 1991; 12: 224–9.
18 Angulo P, Lindr KD. Treatment of non-
alcoholic fatty liver: present and emer-
ging therapies. Semin Liver Dis 2001;
21: 81–8.
19 Berk-Planken II, Hoogerbrugge N, Stolk
RP, Bootsma AH, Jansen H: Atorvastatin
dose-dependently decreases hepatic
lipase activity in type 2 diabetes; effect
of sex and the LIPC promoter variant.
Diabetes Care 2003; 26: 427–32.
20 Clark LT. Treating dyslipemia with sta-
tins: the risk-benefit profile. Am Heart J
2003; 145: 387–9.
21 Funatsu T, Suzuki K, Goto M, et al. Pro-
longed inhibition of cholesterol sı´ntesis
by atorvastatin inhibits apo B-100 and
triglyceride secretion from HEPg2 cells.
Atherosclerosis 2001; 157: 107–15.
22 Harlander JC, Kwo PY, Cummings OW.
Atorvastatin for the treatment of NASH.
Gastroenterology 2001; 120A: 544.
23 Kiyici M, Gulten M, Gurel S, et al.
Ursodeoxycholic acid and atorvastatin
in the treatment of non-alcoholic steato-
hepatitis. Can J Gastroenterol 2003; 17:
713–8.
24 Agrawal S, Bonkovsky HL. Management
of non-alcoholic steatohepatitis. An
analytic review. J Clin Gastroenterol
2002; 35: 253–61.
25 Powell EE, Cooksley WGE, Hanson R,
Searle J, Halliday JW, Powell LW. The
natural history of non-alcoholic steato-
hepatitis: a follow-up study of forty-two
patients for up to 21 years. Hepatology
1990; 11: 74–80.
26 Joseph AE, Saverymuttu SH, al-Sam S,
Cook MG, Maxwell JD. Comparison of
liver histology with ultrasonography in
assessing diffuse parenchyma liver dis-
ease. Clin Radiol 1991; 43: 26–31.
27 Parra JL, Reddy KR. Hepatotoxicity of
hypolipidemic drugs. Clin Liver Dis
2003; 7: 415–33.
28 Gershovich OE, Lyman AE Jr. Liver
function test abnormalities and pruritus
in a patient treated with atorvastatin:
case report and review of the literature.
Pharmacotherapy 2004; 24: 150–4.
29 Perger L, Kohler M, Fattinger K, Flury
R, Meier PJ. Fatal liver failure with
atorvastatin. J Hepatol 2003; 39:
1095–97.
ATORVASTATIN TREATMENT IN NON-ALCOHOLIC FATTY L IVER PATIENTS 1647
ª 2006 The Authors, Aliment Pharmacol Ther 23, 1643–1647
Journal compilation ª 2006 Blackwell Publishing Ltd
本文档为【j3阿托伐他汀治疗非酒精性脂肪肝的试验研究】,请使用软件OFFICE或WPS软件打开。作品中的文字与图均可以修改和编辑,
图片更改请在作品中右键图片并更换,文字修改请直接点击文字进行修改,也可以新增和删除文档中的内容。
该文档来自用户分享,如有侵权行为请发邮件ishare@vip.sina.com联系网站客服,我们会及时删除。
[版权声明] 本站所有资料为用户分享产生,若发现您的权利被侵害,请联系客服邮件isharekefu@iask.cn,我们尽快处理。
本作品所展示的图片、画像、字体、音乐的版权可能需版权方额外授权,请谨慎使用。
网站提供的党政主题相关内容(国旗、国徽、党徽..)目的在于配合国家政策宣传,仅限个人学习分享使用,禁止用于任何广告和商用目的。